Countable Labs closed a $26 million financing round to scale commercial expansion of its single-molecule PCR technology and advance measurable residual disease (MRD) applications for cell and gene therapy and other platforms. The company said proceeds will also support further product development into broader oncology and precision medicine workflows. The fundraise signals continued venture interest in ultrasensitive molecular diagnostics, especially tools that can quantify low-level disease signals for MRD monitoring and therapeutic decision-making. Countable’s reported roadmap focuses on moving its single-molecule PCR approach beyond early research deployments into scalable commercial offerings and expanding to MRD-relevant use cases. For customers, the main near-term outcome is improved availability and implementation support for MRD and gene-therapy analytics where sensitivity and throughput are primary requirements.